Professor, Obstetrics and Gynecology - Gynecologic Oncology, Stanford University Medical Center
Obstetrics & Gynecology
Dr. Jonathan S. Berek, MD
|
|
Give Review
Dr. Jonathan S. Berek practices Obstetrics & Gynecology. He went to Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical university. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He over the years received 4 awards: "CMS Meaningful Use Stage 1 Certification", "Fellow (FACOG)", "Whos Who in Medicine and Healthcare" and "Fellow (FACS)". Jonathan Berek is a published doctor and has 48 publications published. The lastest was: 'Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.' Jonathan Berek accepts Medicare payments and is registered with Medicare.gov.
Publications
- Rethinking ovarian Cancer II: reducing mortality from high-grade serous ovarian Cancer.
- Auranofin displays antiCancer activity against ovarian Cancer cells through FOXO3 activation independent of p53.
- Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian Cancer: a phase I dose-escalation study.
- Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study.
- FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage.
- Current management of vulvar Cancer.
- Personalizing CA125 Levels for Ovarian Cancer Screening.
- A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection.
- Strategies and goals: the future of the International Gynecologic Cancer Society: IGCS Presidential Address.
- Toll-like receptor-3 as a target to enhance bioactivity of Cancer immunotherapy.
- The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial Carcinoma: a Gynecologic Oncology Group study.
- Lymph node-positive stage IIIC ovarian Cancer: a separate entity?
- Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.
- Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian Cancer: the Gynecologic Oncology Group experience.
- Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian Cancer.
- HER-2/neu targeting for recurrent Vulvar Paget's disease A case report and literature review.
- Opportunities and challenges in ovarian Cancer research, a perspective from the 11th Ovarian Cancer action/HHMT Forum, Lake Como, March 2007.
- CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of ...
- Trends in demographic and clinical characteristics in women diagnosed with corpus Cancer and their potential impact on the increasing number of deaths.
- Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus Cancer.
- Vulvar melanoma: a multivariable analysis of 644 patients.
- Impact of the human papilloma vaccine on Cervical cancer.
- Lymphadenectomy in endometrioid uterine Cancer staging: how many lymph nodes are enough? A study of 11,443 patients.
- Influence of the gynecologic oncologist on the survival of ovarian Cancer patients.
- Ovarian conservation at the time of hysterectomy for benign disease.
- Elective oophorectomy for benign gynecological disorders.
- CA125: megadaltons of novel opportunities.
- Prognostic factors for uterine Cancer in reproductive-aged women.
- Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.
- Association of lymphadenectomy and survival in stage I ovarian Cancer patients.
- The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar Carcinoma.
- Patterns and progress in ovarian Cancer over 14 years.
- Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
- Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies.
- Evaluation of vinorelbine in persistent or recurrent nonsquamous Carcinoma of the cervix: a Gynecologic Oncology Group Study.
- Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian Cancer.
- Detection of residual subclinical ovarian Carcinoma after completion of adjuvant chemotherapy.
- Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage Cervical cancer.
- Cervical cancer: an opportunity to prevent and cure.
- Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic m...
- Phase II evaluation of oxaliplatin in previously treated squamous cell Carcinoma of the cervix: a gynecologic oncology group study.
- Progress in the management of gynecologic Cancer: consensus summary statement.
- Biologic and immunologic therapies for ovarian Cancer.
- Simplification of the new Bethesda 2001 classification system.
- Specific keynote: immunological therapy for ovarian Cancer.
- Immunotherapeutic approaches to ovarian Cancer treatment.
Schools
Johns Hopkins University School of Medicine
Harvard Med School Brigham and Women39s Hospital
UCLA School Med
Procedures Preformed
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- Gynecologic Cancer Screening
- View All
Conditions Treated
- Asymptomatic Post-Menopausal Status
- Carcinoma in Situ
- Cervical Cancer
- Cervicitis
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACOG)
- Whos Who in Medicine and Healthcare
- Fellow (FACS)
Education
-
UCLA Medical Center -
Brigham and Women's Hospital -
Johns Hopkins University School of Medicine
Hospital
-
Stanford Health Care -
Lucile Packard Children's Hospital Stanford
Drug Facts
| NPI NUMBER | 1164447900 | |
| NPPES Provider LastName | BEREK | |
| NPPES Provider FirstName | JONATHAN | |
| NPPES Provider ZIPCode | 943052200 | |
| NPPES Provider State | CA | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 24.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164447900 |
| Last Name Of The Provider | BEREK |
| First Name Of The Provider | JONATHAN |
| View All |
Similar Doctors
|
|
Dr. Nelson N. Teng, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natali Aziz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Usha Chitkara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary T. Jacobson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanaa H. Suharwardy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amreen Husain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shannon Maclaughlan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael B. Shaheen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mylene W. Yao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark G. Boddy, MD
This Doctor is OpenDoctor Recommended.
|